Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Lilly and CureVac to develop new cancer vaccines

Lilly and CureVac to develop new cancer vaccines

20th October 2017

Lilly has announced a global immuno-oncology collaboration with CureVac to develop a series of new cancer vaccines.

The work will focus on the development and commercialisation of up to five potential cancer vaccine products based on CureVac's proprietary RNActive technology, with messenger RNA (mRNA) technology used to target cancer cells for a more robust immune response.

Specifically, the technology will be used to deliver mRNA that directs the human immune system to target selected encoded neoantigens, allowing a selective and potent response to be generated to eradicate the cancer.

CureVac is eligible to receive more than $1.7 billion (1.29 billion pounds) in development and commercialisation milestones if all five vaccines are successfully developed, plus an upfront payment of $50 million and an equity investment of €45 million.

Lilly will be responsible for target identification, clinical development and commercialisation, while CureVac handles mRNA design, formulation and manufacturing of clinical supply. The latter company will also retain the option to co-promote the vaccines in Germany.

Dr Greg Plowman, vice-president of oncology research at Lilly, said: "This collaboration reinforces Lilly's commitment to delivering life-changing medicines to treat and cure people living with cancer around the world."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.

We currently have 8 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.